Bradley J. Monk, MD, FACS, FACOG - Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer - a podcast by PVI, PeerView Institute for Medical Education
from 2020-05-15T18:00
Go online to PeerView.com/BBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer. Upon completion of this activity, participants should be better able to: Review the benefits of maintenance therapy on overall patient outcomes in ovarian cancer management, Summarize new evidence on and recent indications for PARP inhibitors as maintenance therapy in the frontline and recurrent advanced ovarian cancer settings, Select appropriate maintenance interventions based on patient and disease characteristics and response to prior therapy in patients with advanced ovarian cancer.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education